January 19, 2016 — Several people who were diagnosed with diabetic ketoacidosis after taking Invokana have filed lawsuits against Janssen Pharmaceuticals.
The first lawsuit was filed by Arthur Portnoff, a man with type-2 diabetes who started taking Invokana in November 2014. Just three months later, he was diagnosed with diabetic ketoacidosis, a life-threatening medical emergency that involves too much acid in the bloodstream.
Portnoff filed the lawsuit (Case No. 15-12-00653) in the Philadelphia Court of Common Pleas in December 2015, just days after the FDA ordered Janssen to add warnings about ketoacidosis to the label on Invokana.
On December 15, a woman from Alabama filed a similar lawsuit (PDF) in the U.S. District Court for the Southern District of Alabama. The plaintiff, Luana Jean Collie, started taking Invokana in December 2014 for the treatment of type-2 diabetes. Soon afterward, she was diagnosed with ketoacidosis.
According to her lawsuit (Case No. 1:15-cv-00636), Collie continues to experience severe physical and emotional pain and suffering, decreased quality of life, and more.
She claims she never would have used Invokana if she had known about the risks. Janssen is accused of negligence for failing to adequately warn about the risks of Invokana. She also accuses Janssen of marketing Invokana for “off-label” (unapproved) uses like weight-loss, reduced blood pressure, and improved blood-sugar control in type-1 diabetes.
Need an Invokana Lawyer in Texas?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact our Texas Invokana lawyers for a free lawsuit review.